Amicus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Amicus Therapeutics

31/07/2025 14:32

Amicus Therapeutics Inc FOLD.OQ reported a quarterly adjusted loss of 7 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -5 cents.  The mean expectation of twelve analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -20 cents to -3 cents per share.

Revenue rose 22.1% to $154.69 million from a year ago; analysts expected $147.07 million.

Amicus Therapeutics Inc's reported EPS for the quarter was a loss of 8 cents​.

The company reported a quarterly loss of $24.42 million.

Amicus Therapeutics Inc shares had risen by 7.0% this quarter and lost 34.9% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 107.8% in the last three months.​

In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Amicus Therapeutics Inc is $15.00, about 59.1% above its last closing price of $6.13

This summary was machine generated from LSEG data July 31 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.12
-0.07
Beat
Mar. 31 2025
-0.05
-0.07
Missed
Dec. 31 2024
0.01
0.05
Beat
Sep. 30 2024
0.00
-0.02
Missed